<DOC>
	<DOCNO>NCT02615184</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness treatment daily ( QD ) oral administration dexlansoprazole 30 60 mg 8 12 week pediatric subject age 1 11 year inclusive , erosive esophagitis ( EE ) ass safety effectiveness dexlansoprazole 15 30 mg compare placebo maintenance heal EE 16 week .</brief_summary>
	<brief_title>A Phase 2 , Double Blind Study Assess Dexlansoprazole Delayed-Release Capsules Healing Erosive Esophagitis ( EE ) Maintenance Healed EE Pediatric Participants</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . Dexlansoprazole test heal erosive esophagitis ( EE ) maintain heal EE pediatric participant age 1 11 year . This study look heal EE follow maintain heal EE child take dexlansoprazole . The study conduct two period ; Healing EE Period Maintenance Healed EE Period . Approximately 80 patient enrol study . Participants randomly assign ( chance , like flip coin ) receive dexlansoprazole 60 mg dexlansoprazole 30 mg 8 12 week Healing EE Period . Participants heal EE confirm endoscopy week 8 12 enter Maintenance Healed EE Period randomly assign receive half heal dose dexlansoprazole , ( i.e. , either 30 mg , dexlansoprazole 15 mg ) , placebo ( capsule look like study drug active ingredient ) . All participant ask take one capsule time day throughout study . All participant ask record time heartburn symptom diary . Subjects complete 16 week Maintenance Healed EE Period ( Week 24 Week 28 applicable ) maintain heal EE confirm endoscopy , enter Post-Treatment Follow Period 3 month last dose study drug . During period subject continue complete symptom questionnaire daily eDiaries return clinic visit month . Subjects require invasive procedure treatment proton pump inhibitor ( PPI ) histamine 2-receptor antagonist ( H2RA ) gastroesophageal reflux disease ( GERD ) /EE discontinue Post-Treatment Follow-up Period Final Study Visit perform . This multi-center trial conduct worldwide . The overall time participate study 40 week . Participants make multiple visit clinic include final visit 3 month last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant ( age appropriate ) and/or parent ( ) legal guardian capable understand comply protocol requirement . 2 . Prior studyspecific procedure perform , informed consent assent form must sign dated parent ( ) legal guardian participant respectively , appropriate . 3 . Has medical history symptom gastroesophageal reflux disease ( GERD ) least 3 month prior Screening . 4 . Has medical history least 1 fail attempt withdrawal prior proton pump inhibitor ( PPI ) /acid suppressive therapy return symptom upon withdrawal . 5 . Has meet electronic diary ( eDiary ) qualification criterion assess Pediatric GERD Symptom Daily Diaries ( PGSDD ) , define hurt burn stomach , chest , throat least 3 7 consecutive day Screening Period . ( Note : If endoscopy perform within 1 week signing informed consent assent use confirm diagnosis erosive esophagitis ( EE ) , participant need meet criterion ) . 6 . Has endoscopic evidence EE HetzelDent ( HD ) Grade ≥2 base screen endoscopy perform either Screening Period within 1 week prior sign inform consent assent ( applicable ) . An endoscopy perform within 1 week prior sign inform consent assent , applicable , acceptable replacement Screening endoscopy EE document HD classification scale criterion previously describe , protocolrequired biopsy collect endoscopic picture obtain . 7 . Is male female age 1 11 year inclusive Screening . 1 . Has evidence cardiovascular , pulmonary , central nervous system , hepatic , hematopoietic , renal , metabolic disorder , severe allergy , asthma , allergic skin rash suggest uncontrolled , clinically significant underlying disease condition ( disease study ) , may impact ability participant participate potentially confound study result . 2 . Has coexist disease affect esophagus ( eg , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiation therapy cryotherapy esophagus , caustic physiochemical trauma sclerotherapy esophagus . 3 . Has find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion underlie disease might interfere conduct trial . 4 . Has history hypersensitivity allergy dexlansoprazole component dexlansoprazole PPI ( include lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole ) antacid . 5 . Is required take exclude medication anticipate participant require treatment least 1 disallow concomitant medication study evaluation period . 6 . Has condition may require inpatient surgery course study . 7 . Has know history Barrett 's dysplastic change esophagus . 8 . Has know history eosinophilic esophagitis ( EoE ) endoscopic finding suggestive EoE ( ≥15 eosinophils per highpowered field [ HPF ] ) . 9 . Has history celiac disease , confirm histology test positive tissue transglutaminase ( tTG ) antibody . 10 . Has history inflammatory bowel disease , irritable bowel syndrome . 11 . Has active gastric duodenal ulcer within 4 week prior Day 1 . 12 . Requires dilatation esophageal strictures and/or stricture prevent passage endoscope Screening endoscopy . Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) acceptable . 13 . A female participant reach menarche . 14 . Is know positive human immunodeficiency virus ( HIV ) . 15 . Has current clinical history ZollingerEllison syndrome hypersecretory condition . 16 . Has history gastric , duodenal , esophageal surgery except simple oversew ulcer . A history gastric tube and/or percutaneous endoscopic gastrostomy ( PEG ) placement allow . 17 . Had acute upper gastrointestinal hemorrhage within 4 week prior endoscopy . 18 . Has donate lose &gt; 10 % total blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 19 . Has know history alcohol abuse illegal drug use within past 12 month prior first dose study drug . 20 . Has screen abnormal laboratory value suggest clinically significant underlying disease condition may prevent participant enter study ; participant : creatinine &gt; 1.5 mg/dL , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ×ULN ) , total bilirubin &gt; 2.0 mg/dL AST/ALT elevate limit normal value . 21 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study may consent assent duress . Students institution/research facility supervision , subordinate role , investigator also ineligible . 22 . The participant , opinion investigator , unlikely comply protocol unsuitable reason . 23 . Has participate another clinical study and/or receive investigational compound within 30 day prior Screening . 24 . Tests positive H. pylorus . However , participant positive receive therapeutically approve eradication therapy within past 6 month allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>